Altium Wealth Management’s Alaunos Therapeutics TCRT Stock Holding History

Altium Wealth Management’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$19K	Hold	100	–	–	﹤0.01%	369
2022 Q1	$10K	Hold	100	–	–	﹤0.01%	376
2021 Q4	$16K	Hold	100	–	–	﹤0.01%	388
2021 Q3	$27K	Hold	100	–	–	﹤0.01%	376
2021 Q2	$40K	Hold	100	–	–	﹤0.01%	373
2021 Q1	$54K	Hold	100	–	–	﹤0.01%	375
2020 Q4	$38K	Hold	100	–	–	﹤0.01%	347
2020 Q3	$38K	Hold	100	–	–	﹤0.01%	335
2020 Q2	$49K	Hold	100	–	–	0.01%	320
2020 Q1	$37K	Hold	100	–	–	0.01%	321
2019 Q4	$71K	Hold	100	–	–	0.01%	281
2019 Q3	$64K	Hold	100	–	–	0.01%	280
2019 Q2	$87K	Hold	100	–	–	0.01%	270
2019 Q1	$58K	Hold	100	–	–	0.01%	281
2018 Q4	$28K	Hold	100	–	–	0.01%	271
2018 Q3	$48K	Hold	100	–	–	0.01%	294
2018 Q2	$45K	Hold	100	–	–	0.01%	263
2018 Q1	$59K	Hold	100	–	–	0.02%	165
2017 Q4	$62K	Buy	+100	New	+$71.8K	0.03%	155

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Altium Wealth Management's TCRT Position: Q2 2022 in Review

Altium Wealth Management held its Alaunos Therapeutics (TCRT) position steady in Q2 2022 at 100 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #369.

Altium Wealth Management first reported a position in TCRT in Q4 2017 and has held it in 19 quarters since. The position peaked at $87K in Q2 2019. 124 funds tracked by Wall St. Rank hold TCRT as of Q2 2022.

Altium Wealth Management held 100 shares of Alaunos Therapeutics worth $19K as of Q2 2022.
Altium Wealth Management left its Alaunos Therapeutics share count unchanged in Q2 2022.
Alaunos Therapeutics made up ﹤0.01% of Altium Wealth Management's portfolio in Q2 2022, its #369 holding.
Altium Wealth Management first reported a position in Alaunos Therapeutics in Q4 2017 and has held it in 19 quarters since.
Altium Wealth Management's Alaunos Therapeutics position peaked at $87K in Q2 2019.
124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2022.

Based on Altium Wealth Management's 13F filing for Q2 2022, filed 22 Jul 2022.